(Bloomberg) -- The effort to convert Pfizer Inc.’s former New York headquarters into residences secured financing to help developers forge ahead on the project near Grand Central Terminal.

The firm paid $140M to the estate of late real estate investor Bernard Kayden for the land underneath the office building at 235 E. 42nd St., according to documents filed Wednesday. Pincus Co ...

Eventually, he moved to New York to work at Pfizer headquarters, and held a number of senior roles within the company, both within Animal Health (now spun-out into Zoetis), and elsewhere.

Pfizer appoints former J&J executive to lead obesity drug development Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

Also, 25 percent of the luxury apartments are designated as affordable, and will target those making $80,000 to $100,000 per ...

Pharma firms are among many pausing diversity programmes and promising domestic investment ...

Pfizer (PFE) stock is lower in Tuesday's session even after the pharmaceutical giant beat top- and bottom-line expectations for its third quarter and raised its full-year outlook. Track all ...

Pfizer generated strong growth last year despite a significant drop in COVID revenue. The company's business is solid, and its growth prospects are encouraging. Investors, however, remain ...